

Meeting Venue - Hotel Garden Via Custoza 2 - Siena, Italy

Scientific Secretariat



10th ANNIVERSARY 2022


NIBIT Foundation ONLUS

Phone: +39 3490582533 segreteria@fondazionenibit.org www.fondazionenibit.org www.thinktank-nibitfoundation.org Organizing Secretariat



RAY HC srl

Via Bernina 7, 20158, Milano, Italy Via Cardinal De Luca 22, 00196, Roma, Italy M: +39 3939391755




October **3**rd-**5**th **2024**

 $\Pi / \Pi \Pi$



10th ANNIVERSARY 2022







A VISION OF I-OCALL FOR ACTIONS







The Think Tank is promoted by the NIBIT Foundation in collaboration with the Parker Institute for Cancer Immunotherapy and the World Immunotherapy Council

ctober

(CET)

Welcome to the VIII Siena I-O Think Tank 17:30 - 18:00 Michele Maio (Siena, Italy), Bernie Fox (Portland, USA), Ramy Ibrahim (San Francisco, USA)

The Investors decision making process in non-profit research 18:00 - 19:40

Chairs: Ramy Ibrahim (San Francisco, USA), Michael Lahn (Geneva, Switzerland)

The PICI | John Connolly (San Francisco, USA) 18:00 - 18:15

The NIBIT Foundation | Michele Maio (Siena, Italy) 18:15 - 18:30

The Analyst | Asthika Goonewardene (New York, USA) 18:30 - 18:50

Round Table Led by Ramy Ibrahim (San Francisco, USA) 18:50 - 19:40 Panelists: Chairs, Speakers, Bernie Fox (Portland, USA)

Wine and Cheese 20:30

Aims of the meeting will be:

update for all participants.

1. Sharing the vision on highly selected I-O topics

attendees in highly interactive discussions.

2. Implementing new collaborations (pre-clinical/clinical/educational) among participants and with the organizational (and financial) support of the scientific Co-Organizing entities

The VIII Think Tank of the Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation is focused on sharing with the enlarged scientific community the research findings and

initiatives of the **NIBIT Foundation** research team in the context of the rapidly evolving field of

cancer immunotherapy worldwide. A great opportunity of professional exchange and scientific


As for the past editions, the Meeting is organized in collaboration with **The Parker Institute for**

Cancer Immunotherapy (PICI) in San Francisco and the World Immunotherapy Council (WIC).

During the event worldwide acknowledged scientists in the field of cancer immunotherapy will

debate about pre-selected scientific, translational and clinical research topics, engaging the

- 3. Presenting research projects/ideas by pre-selected (also through WIC) young investigators in the identified topics of the meeting to be discussed and eventually hosted in Institutions participating to the Think Tank
- 4. Generating a white paper manuscript



October **4**th 2024

 08:45 - 13:00 SESSION 1 Focus on the PICI and NIBIT Foundation research: opportunities for joint actions? 08:45 - 09:00 Chairs: Barbara Seliger (Brandenburg, Halle, Leipzig, Germany), Volker Wacheck (Taiho Oncology, Switzerland), Lorenzo Moretta (Rome, Italy) 09:00 - 09:30 PICI: Dual functioning antibodies Samir Khleif (Washington DC, USA) 09:30 - 10:00 PICI: Cell therapy across PICI portfolio Companies John Connolly (San Francisco, USA) 10:00 - 10:30 PICI: Prostate Cancer as a Paradigm of IO Resistance Sumit Subudhi (Houston, USA) 10:30 - 11:00 Coffee Break 11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabro (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy) 12:30 - 13:00 Conclusions and call for actions Chairs 	(CET)	
Opportunities for joint actions? Chairs: Barbara Seliger (Brandenburg, Halle, Leipzig, Germany), Volker Wacheck (Taiho Oncology, Switzerland), Lorenzo Moretta (Rome, Italy) PICI: Dual functioning antibodies Samir Khleif (Washington DC, USA) PICI: Cell therapy across PICI portfolio Companies John Connolly (San Francisco, USA) PICI: Prostate Cancer as a Paradigm of IO Resistance Sumit Subudhi (Houston, USA) Coffee Break The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	08:45 - 13:00	• • • • • • • • • • • • • • • • • • •
 O8:45 - 09:00		
 09:00 - 09:30 PICI: Dual functioning antibodies Samir Khleif (Washington DC, USA) 09:30 - 10:00 PICI: Cell therapy across PICI portfolio Companies John Connolly (San Francisco, USA) 10:00 - 10:30 PICI: Prostate Cancer as a Paradigm of IO Resistance Sumit Subudhi (Houston, USA) 10:30 - 11:00 Coffee Break 11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy) 	08:45 - 09:00	
 10:30 - 10:00 PICI: Cell therapy across PICI portfolio Companies John Connolly (San Francisco, USA) 10:00 - 10:30 PICI: Prostate Cancer as a Paradigm of IO Resistance Sumit Subudhi (Houston, USA) 10:30 - 11:00 Coffee Break 11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy) 		Volker Wacheck (Taiho Oncology, Switzerland), Lorenzo Moretta (Rome, Italy)
10:00 - 10:30 PICI: Prostate Cancer as a Paradigm of IO Resistance Sumit Subudhi (Houston, USA) 10:30 - 11:00 Coffee Break 11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	09:00 - 09:30	PICI: Dual functioning antibodies Samir Khleif (Washington DC, USA)
 10:30 - 11:00 Coffee Break 11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy) 	09:30 - 10:00	PICI: Cell therapy across PICI portfolio Companies John Connolly (San Francisco, USA)
11:00 - 11:30 The EPICA Consortium: DNA methylation subsets in metastatic melanoma: prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	10:00 - 10:30	PICI: Prostate Cancer as a Paradigm of 10 Resistance Sumit Subudhi (Houston, USA)
prognostic significance and reprogramming by DNMT inhibition Andrea Anichini (Milan, Italy) 11:30 - 12:00 NIBIT Foundation: Epigenetically-driven response to ICI therapy of melanoma and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	10:30 - 11:00	Coffee Break
and lung cancer Anna Maria Di Giacomo (Siena, Italy) 12:00 - 12:30 NIBIT Foundation: Epigenetically-driven response to ICI therapy of pleural mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	11:00 - 11:30	prognostic significance and reprogramming by DNMT inhibition
mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli (Miami, USA/Naples, Italy)	11:30 - 12:00	
12:30 - 13:00 Conclusions and call for actions Chairs	12:00 - 12:30	mesothelioma Luana Calabrò (Ferrara, Italy), Michele Ceccarelli
	12:30 - 13:00	Conclusions and call for actions Chairs
13:00 - 14:30 Lunch	13:00 - 14:30	Lunch

(CET)

14:30 - 18:30 SESSION 2 | A future beyond ICI or ICI-based? 14:30 - 14:45 Chairs: Patrick Garcia (GSK, Switzerland), Pedro Romero (Lausanne, Switzerland), Bernie Fox (Portland, USA) 14:45 - 15:15 The achievements of 15 years of ICI | Alexander Eggermont (Utrecht, The Netherlands) 15:15 - 15:45 Bispecific antibodies in development | Kim Young (Regeneron, USA) Novel antibody-cytokine fusions | Dario Neri (Philogen, Switzerland)

- 16:15 16:45 **Strategy evolution in oncology** | Cosimo Paga (Bristol Myers Squibb, Italy)
- 16:45 17:15 **Tea Break**
- 17:15 17:45 **Cancer Dark Matter Vaccine: Clinical Responses** | Rom Leidner (Portland, USA)
- 17:45 18:15 Leveraging mRNA Technology for Antigen Based Immuno-Oncology Therapies

000000

- Wei Zheng (Moderna, USA)
- 18:15 18:30 **Conclusions and call for actions** | Chairs
- 18:30 19:15 The NIBIT Foundation Annual Lecture: Keep your eyes on the prize:
 - adventures in drug development | Renzo Canetta (Madison, USA)
 - Introduced by Michele Maio (Siena, Italy)
- 20:15 **Social Dinner**

October **5**th **2024**

(CET)

09:00-13:00 **SESSION 3** | Novel technologies to dissect the tumor-host ecosystem: single-cells, spatial transcriptomics and AI

09:00 - 09:15 *Chairs:* Zlatko Trajanoski (Innsbruck, Austria), Michele Ceccarelli (Miami, USA/Naples, Italy), Catherine Sautès-Fridman (Paris, France)

09:15 - 09:45 **Analyzing tumor microenvironment** | Wolf Hervé Fridman (Paris, France)

09:45 - 10:15 The spatial transcriptomic landscape of experimental inflammation-induced colorectal

cancer | Eduardo Villablanca (Stockholm, Sweden)

10:15 - 10:45 Leveraging anatomical scales to understand tissue biology and organ architecture

in health and disease | André Rendeiro (Wien, Austria)

10:45 - 11:15 **Coffee Break**

11:15 - 11:45 Artificial Intelligence-based biomarkers for immunotherapy

Marta Ligero (Dresden, Germany)

11:45 - 12:15 Mapping the spatial architecture of the TME in lung tumour evolution

Mihaela Angelova (London, UK)

12:15 - 12:45 **High resolution single-cell atlases in cancer** | Zlatko Trajanoski (Innsbruck, Austria)


12:45 - 13:00 **Conclusions and call for actions** | Chairs

(CET)

13:00 - 13:30 **SESSION 4** | The IX Siena I-O Think Tank 2025

Chairs: Michele Maio (Siena, Italy), Bernie Fox (Portland, USA), Ramy Ibrahim (San Francisco, USA)

Ideas and topics for the IX Siena 2025 Think Tank (October 2-4, 2025)



SCIENTIFIC ORGANIZERS

- Michele Maio University of Siena and Center for Immuno-Oncology, Siena (Italy)
- **Bernie Fox** Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland (USA)
- Ramy Ibrahim Parker Institute for Cancer Immunotherapy. San Francisco (USA)

FACULTY

- Mihaela Angelova (London, UK)
- Andrea Anichini (Milan, Italy)
- Luana Calabrò (Ferrara, Italy)
- Renzo Canetta (Madison, USA)
- Michele Ceccarelli (Miami, USA /Naples, Italy)
- **John Connolly** (San Francisco, USA)
- Anna Maria Di Giacomo (Siena, Italy)
- Alexander Eggermont (Utrecht, The Netherlands)
- Bernie Fox (Portland, USA)
- Wolf Hervé Fridman (Paris, France)
- Patrick Garcia (GSK. Switzerland)
- Asthika Goonewardene (New York, USA)
- Ramy Ibrahim (San Francisco, USA)
- Samir Khleif (Washington DC, USA)
- Michael Lahn (Geneva, Switzerland)
- Rom Leidner (Portland, USA)
- Marta Ligero (Dresden, Germany)

- Michele Maio (Siena, Italy)
- Lorenzo Moretta (Rome, Italy)
- Dario Neri (Philogen, Switzerland)
- Cosimo Paga (Bristol Myers Squibb, Italy)
- André Rendeiro (Wien, Austria)
- **Pedro Romero** (Lausanne, Switzerland)
- Catherine Sautès-Fridman (Paris, France)
- Barbara Seliger (Brandenburg, Halle, Leipzig, Germany)
- **Sumit Subudhi** (Houston, USA)
- Zlatko Trajanoski (Innsbruck, Austria)
- Eduardo Villablanca (Stockholm, Sweden)
- **Volker Wacheck** (Taiho Oncology, Switzerland)
- **Kim Young** (Regeneron, USA)
- Wei Zheng (Moderna, USA)



INVITEE FACULTY

- Maresa Altomonte (Siena, Italy)
- Paola Arcidiacono (MSD, Italy)
- **Gregorio Aversa** (Vancouver, Canada)
- Daniele Banfi (Milan, Italy)
- Beatrice Bodega (Milan, Italy)
- Jennifer Burbea (Rome, Italy)
- Elisabetta Calabrese (Bristol Myers Squibb, Italy)
- Roberto Camerini (Rome, Italy)
- Francesca Pia Caruso (Naples, Italy)
- Sandra Coral (Siena, Italy)
- Andrea Corsi (Radiomics.Bio, Belgium)
- **Giorgio Costacurta** (Pordenone, Italy)
- Alessia Covre (Siena, Italy)
- Luca Danelli (Nature, UK)
- **Gianni D'Errico** (Toscana Life Sciences, Italy)
- Francesco Dotta (Siena, Italy)
- Elisabetta Ferretti (Rome. Italy)
- Elisabetta Fratta (Aviano, Italy)

- Maria Lofiego (Siena, Italy)
- Marco Merlano (Turin, Italy)
- Mauro Merlo (Pierre Fabre, Italy)
- **Roberto Molinaro** (XGEN Venture, Italy)
- Roberta Mortarini (Milan, Italy)
- Luigi Nezi (Milan, Italy)
- Ulrich Pfeffer (Genoa, Italy)
- Carlo Ennio Michele Pucillo (Udine, Italy)
- Francesco Rao (Bristol Mayer Squibb, Italy)
- **Gaetano Romano** (OncoTargets and Therapy, UK)
- Maria Sofia Rosati (GSK. Italy)
- Florian Schuster (Bit Bio, UK)
- Luca Sigalotti (Aviano, Italy)
- Michael Smith (Milan, Italy)
- Marko Spasic (San Francisco, USA)
- **Rossella Tufano** (Naples, Italy)





PROMOTED BY







SUPPORTERS





PLATINUM SPONSOR





I Bristol Myers Squibb[™]

SILVER SPONSOR



BRONZE SPONSORS







ENDORSERS













